Evaluation of the Impact of Therapeutic Education in Patients with Multiple Myeloma at Constantine University Hospital Center
Main Article Content
Abstract
.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
How to Cite
References
[1] Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al.
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv52–61.
https://doi.org/10.1093/annonc/mdx096.
[2] Beck K, Sandahl T, Ailawadhi S, Khera N, Jensen C. Multiple Myeloma: Current Clinical Landscape and Compounding Costs.
Curr Hematol Malig Rep 2023;18:201–15. https://doi.org/10.1007/s11899-023-00705-8.
[3] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-386. https://doi.org/10.1002/ijc.29210.
[4] Mateos M-V, Ocio EM, Paiva B, Rosiñol L, Martínez-López J, Bladé J, et al. Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev 2015;29:387403. https://doi.org/10.1016/j.blre.2015.06.001.
[5] Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race,
and ethnicity in the United States. Blood Adv. 2017;1:282–7. https://doi.org/10.1182/bloodadvances.2016002493.
[6] Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122–8.
https://doi.org/10.1038/leu.2013.313.
[7] Fonseca R, Abouzaid S, Bonafede M, Cai Q,Parikh K, Cosler L, et al. Trends in overall survival and costs of multiple myeloma, 20002014. Leukemia 2017;31:1915–21. https://doi.org/10.1038/leu.2016.380.
[8] Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and
the impact of novel therapies. Blood 2008;111:2516–20. https://doi.org/10.1182/blood-2007-10116129.
[9] Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R, et al. Patient-reported preferences for oral versus intravenous
administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence 2016;10:1609–21. https://doi.org/10.2147/PPA.S106629.
[10] Faithfull S, Deery P. Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. Eur J Oncol Nurs 2004;8 Suppl 1:S54-62. https://doi.org/10.1016/j.ejon.2004.06.009.
[11] Chari A, Romanus D, DasMahapatra P, Hoole M, Lowe M, Curran C, et al. Patient-Reported Factors in Treatment
Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Oncologist 2019;24:1479–87. https://doi.org/10.1634/theoncologist.2018
[12] DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol 1998;16:2557–67.
https://doi.org/10.1200/JCO.1998.16.7.2557.
[13] Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002;94:652–61. https://doi.org/10.1093/jnci/94.9.652.
[14] Ranchon F, Bouret C, Charpiat B, Leboucher G. Sécurisation de l’emploi des chimiothérapies anticancéreuses administrables
par voie orale. Le Pharmacien Hospitalier 2009;44:36–44. https://doi.org/10.1016/j.phhp.2008.12.002.
[15] Nightingale G, Hajjar E, Pizzi LT, Wang M, Pigott E, Doherty S, et al. Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer. J Geriatr Oncol 2017;8:296–302. https://doi.org/10.1016/j.jgo.2017.04.005.
[16] Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin
2009;59:56–66. https://doi.org/10.3322/caac.20004
[17] Mian H, Fiala M, Wildes TM. Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk 2020;20:98104.e1. https://doi.org/10.1016/j.clml.2019.09.618.
[18] Dempsey JL, Johns A, Rosko AE, Lazarus HM. The pharmacologic management of multiple myeloma in older adults. Expert
2019;20:887–902. Opin Pharmacother https://doi.org/10.1080/14656566.2019.1577822. Noga SJ, Rifkin RM, Manda S, Birhiray RE, Lyons RM, Whidden P, et al. Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study. 2019;134:3168. Blood https://doi.org/10.1182/blood-2019-124784.
[20] l’Europe O mondiale de la SB régional . Education thérapeutique du patient : programmes de formation continue pour professionnels de soins dans le domaine de la prévention des maladies chroniques : recommandations d’un groupe de travail de
l’O.M.S. Organisation mondiale de la Santé. Bureau régional de l’Europe; 1998.
[21] Gatto F. L’éducation du patient est nécessaire au succès d’une thérapie ou tout n.d.
[22] Girerd X, Hanon O, Anagnostopoulos K, Ciupek C, Mourad JJ, Consoli S. [Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic]. 2001;30:1044–8.
[23] Presse Med Comprendre le myélome multiple. Boulogne-Billancourt] [Lille: Institut national du cancer, INCa AF3M, Association
française des malades du myélome multiple; 2015.
[24] Fiche d’information ENDOXAN® (Cyclophosphamide) Ref : 3C-Inf/Form-106-V1-16/09/2015 n.d.
[25] CYCLOPHOSPHAMIDE Endoxan : http://www.onco-npdc.fr/outilsregionaux n.d.
[26] Cyclophosphamide ENDOXAN® Fiche Patient V2, juin 2022 n.d.
[27] Cyclophosphamide ENDOXAN® Fiche Professionnels de santé V2, juin 2022 n.d.
[28] Fiche ALKERAN® Patient Version V1-5 / février 2014 Groupe VOCC Bretagne / Pays de la Loire n.d.
[29] Fiche ALKERAN® professionnels de santé Version de janvier 2016 Rédigée par l’OMéDIT n.d.
[30] Fiche d’information patient ALKERAN® (Melphalan) Ref : 3CInf/Form-003-V2-04/09/2015 n.d.
[31] Fiche Patient - Lénalidomide - V2 - Mai 2022 ©OMEDIT Bretagne, Normandie et Pays de la Loire n.d.
[32] GUIDE DE RETROCESSION DES IMID Immunomodulateurs Thalidomide®, Revlimid®, Imnovid® Avril 2017 n.d.
[33] Melphalan - Prednisone -Velcade , www.onco-npdc.fr/outils n.d.
[34] Melphalan ALKERAN® . FICHE CONSEIL Professionnel n.d.
[35] Melphalan ALKERAN® Fiche Patient V2, octobre 2022 n.d.
[36] Melphalan ALKERAN® Fiche Professionnels de santé V2, octobre 2022 n.d.
[37] Normandie Validée par le Réseau Onco-Normand - 1 - ALKERAN® Melphalan n.d.
[38] Velcade -Thalidomide - Dexamethasone, www.onco-npdc.fr/outils n.d.
[39] Fiche Patient – Thalidomide – V2 – Avril 2021 ©OMEDIT Bretagne, Normandie et Pays de la Loire n.d.
[40] Fiche Professionnels de santé - Lénalidomide - V2 - Mai 2022 ©OMEDIT Bretagne, Normandie et Pays de la Loire n.d.
[41] Fiche Professionnels de santé – Thalidomide – V2 – Avril 2021 ©OMEDIT Bretagne, Normandie et Pays de la Loire n.d.
[42] Vivre avec le myélome multiple par Janssen - Issuu 2022. https://issuu.com/issuujanssen/docs/myelome multiple_fr_issuu (accessed October 27, 2023).
[43] Le myélome multiple par Krebsliga Schweiz - Issuu 2018. https://issuu.com/krebsliga/docs/lemyelome-multiple- 021082012111 (accessed October 27, 2023).
[44] Amine BM, BOUDJERRA Nadia, HAMDI-LEZZAR Selma, SAIDI Mahdia, Khadidja, AIT-ALI Hocine, et al.
Impact of age and demographic transition on hematological malignancies in Algeria: Metaanalysis study covering a period from 1992 to 2021 (30 years) 2022. https://doi.org/10.5281/ZENODO.7455096.
[45] Fall S, Dieng F, Diouf C, Djiba B, Ndao AC, Ndiaye FSD. Profil diagnostique et évolutif du myélome multiple au Sénégal:
étude monocentrique de 2005 à 2016. Pan Afr Med J 2017;27:262. https://doi.org/10.11604/pamj.2017.27.262.13164.
[46] Bouatay A, Hizem S, Ben Youssef Y, Sayari F, Braham N, Khélif A, et al. Myélome multiple : aspect clinique, diagnostic biologique et pronostic. ImmunoAnalyse & Biologie Spécialisée 2013;28:30–5. https://doi.org/10.1016/j.immbio.2012.09.001.
[47] Myélome multiple - Hématologie et Myeloma Leuk oncologie. Édition professionnelle du Manuel MSD n.d. https://www.msdmanuals.com/fr/professional/h%C3%A9matologie-etoncologie/troubles- /my%C3%A9lome-multiple (accessed November 5, 2023).
[48] Moreau P, Miguel JS, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology 2017;28:iv52–61. https://doi.org/10.1093/annonc/mdx096.
[49] Callander NS, Baljevic M, Adekola K, Anderson LD, Campagnaro E, Castillo JJ, et al. NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022: Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network 2022;20:8–19. https://doi.org/10.6004/jnccn.2022.0002.
[50] Landgren O, Graubard BI, Katzmann JA, Kyle RA, Ahmadizadeh I, Clark R, et al. Racial disparities in the prevalence of
monoclonal gammopathies: a populationbased study of 12 482 persons from the National Health Examination and Survey. 2014;28:1537–42. Nutritional Leukemia https://doi.org/10.1038/leu.2014.34.
[51] Bhatnagar V, Wu Y, Goloubeva OG, KT, Milliron TE, Harris CG, et al. Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study. Cancer 2015;121:1064–70. https://doi.org/10.1002/cncr.29160.
[52] Bird S, Cairns D, Menzies T, Boyd K, F, Cook G, et al. Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clin Lymphoma 2021;21:667–75. https://doi.org/10.1016/j.clml.2021.04.013.
[53] Xu L, Wang X, Pan X, Wang X, Wang Q, Wu B, et al. Education level as a predictor of survival in patients with multiple myeloma. BMC Cancer 2020;20:737. https://doi.org/10.1186/s12885-020-071785.
[54] Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, et al. Maintenance With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. JNCI: Journal of the National Cancer Institute 2016;108:djv342.https://doi.org/10.1093/jnci/djv342.
[55] Sverrisdóttir IS, Rögnvaldsson S, Thorsteinsdottir S, Gíslason GK, Aspelund T, Turesson I, et al. Comorbidities in multiple myeloma and implications on survival: A population-based study. European Journal of Haematology 2021;106:774–82.https://doi.org/10.1111/ejh.13597.
[56] Moreau J, Hammoudi N, Marthey L, Trang-Poisson C, Nachury M, Altwegg R, et al. Impact of an Education Programme on IBD Patients’ Skills: Results of a
Randomised Controlled Multicentre Study [ECIPE]. J Crohns Colitis 2021;15:432–40. https://doi.org/10.1093/ecco-jcc/jjaa195.
[57] Vaucourt J. Education thérapeutique du patient sur les anticancéreux par voie orale en hématologie à l’hôpital de Mercy: participation à la préparation des séances et à la mise en place d’outils éducatifs n.d.
[58] Périchou J, Ranchon F, Herledan C, Huot L, Larbre V, Carpentier I, et al. drugs in multiple myeloma: Impact of the SCARMET(Self CARe and MEdication Toxicity) educational intervention on outpatients’ knowledge to manage adverse effects. PLoS
One 2020;15:e0243309. https://doi.org/10.1371/journal.pone.0243309.
[59] Bruttomesso D, Gagnayre R, Leclercq D, Crazzolara D, Busata E, d’Ivernois J-F, et al. The use of degrees of certainty to evaluate knowledge. Patient Educ Couns 2003;51:29–37. https://doi.org/10.1016/s07383991(02)00226-4.
[60] Feiten S, Chakupurakal G, Feustel HP, Maasberg M, Otremba B, Ehscheidt P, et al. High adherence of patients with multiple myeloma who receive treatment with immunomodulatory drugs (IMIDS) in hematology/oncology group practices in Germany. Support Care Cancer 2019;27:4265–71. https://doi.org/10.1007/s00520-019-047214.
[61] Cransac A, Aho S, Chretien M-L, Giroud M, Caillot D, Boulin M. Adherence to immunomodulatory drugs in patients with
multiple myeloma. PLoS One 2019;14:e0214446. https://doi.org/10.1371/journal.pone.0214446.
[62] Smaje A, Weston-Clark M, Raj R,Orlu M, Davis D, Rawle M. Factors associated with medication adherence in older patients: A systematic review. AGING MEDICINE 2018;1:254–66. https://doi.org/10.1002/agm2.12045.
[63] Cheen MHH, Tan YZ, Oh LF, Wee HL, Thumboo J. Prevalence of and factors associated with primary medication nonadherence in chronic disease: A systematic review and meta-analysis. International Journal of Clinical Practice 2019;73:e13350.
https://doi.org/10.1111/ijcp.13350.
[64] Mhammedi SA, Hamdi F, Benabdelhak M, Bentata Y, Haddiya I. L’observance thérapeutique: un autre défi à relever chez l’hémodialysé chronique. Pan Afr Med J 2019;33:28. https://doi.org/10.11604/pamj.2019.33.28.9448.
[65] Sari N, Osman M. The effects of patient education programs on medication use among asthma and COPD patients: a propensity score matching with a difference-in-difference regression approach. BMC Health Serv Res 2015;15:332.
https://doi.org/10.1186/s12913-015-09986.
[66] Zerbit J, Chevret S, Bernard S, Kroemer M, Ablard C, Harel S, et al. Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study. Ann Hematol 2020;99:1615–25.
https://doi.org/10.1007/s00277-020-04045y.
[67] Gavrilova A, Bandere D, Rutkovska I, Šmits D, Mauriņa B, Poplavska E, et al. Knowledge about Disease, Medication
Therapy, and Related Medication Adherence Levels among Patients with Hypertension. Medicina (Kaunas) 2019;55:715.
https://doi.org/10.3390/medicina55110715.
[68] Milosavljevic A, Aspden T, Harrison J. Community pharmacist-led interventions and their impact on patients’ medication
adherence and other health outcomes: a systematic review. Int J Pharm Pract 2018;26:387–97.
https://doi.org/10.1111/ijpp.12462.
[69] Mes MA, Katzer CB, Chan AHY, Wileman V, Taylor SJC, Horne R. Pharmacists and medication adherence in asthma: a systematic review and metaanalysis. Eur Respir J 2018;52:1800485. https://doi.org/10.1183/13993003.004852018.
[70] Wilhelmsen NC, Eriksson T. Medication adherence interventions and outcomes: an overview of systematic reviews. Eur J Hosp Pharm 2019;26:18792. https://doi.org/10.1136/ejhpharm-2018001725.
[71] Andersson M, Garfield S, Eliasson L, Jackson C, Raynor DK. Delivery of patient adherence support: a systematic review of
the role of pharmacists and doctors. PI 2014;6:31–42. https://doi.org/10.2147/PI.S46647.